A. Freifeld, E. Bow, K. Sepkowitz, M. Boeckh, J. Ito et al., Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.29, issue.526, p.5693, 2011.
DOI : 10.1086/591060

D. Averbuch, C. Orasch, C. Cordonnier, D. Livermore, M. Mikulska et al., European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the, 4th European Conference on Infections in Leukemia, 2011.

P. Pizzo, K. Robichaud, F. Gill, F. Witebsky, A. Levine et al., Duration of empiric antibiotic therapy in granulocytopenic patients with cancer, The American Journal of Medicine, vol.67, issue.2, p.194200, 1979.
DOI : 10.1016/0002-9343(79)90390-5

S. Schimpff, W. Satterlee, V. Young, A. Serpick, W. Kern et al., Empiric therapy with carbenicillin and 4th-generation cephalosporin + aminoglycosides: comparative study Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy, Am J Hematol. déc Clin Infect Dis. 1 août, vol.7137, issue.43, p.3829, 2002.

C. Viscoli, A. Cometta, W. Kern, R. Bock, M. Paesmans et al., Piperacillin???tazobactam monotherapy in high-risk febrile and neutropenic cancer patients, Clinical Microbiology and Infection, vol.12, issue.3, p.2126, 2006.
DOI : 10.1111/j.1469-0691.2005.01297.x

URL : https://doi.org/10.1111/j.1469-0691.2005.01297.x

M. Paul, Y. Dickstein, A. Schlesinger, S. Grozinsky-glasberg, K. Soares-weiser et al., Betalactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia
DOI : 10.1002/14651858.cd003038.pub2

URL : http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003038.pub2/pdf

M. Paul, Y. Dickstein, S. Borok, L. Vidal, L. Leibovici et al., Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study, Cochrane Database Syst Rev. Eur J Clin Microbiol Infect Dis. déc Clin Infect Dis. juill, vol.11225, issue.121, pp.3914-11897906927, 1993.

L. Slobbe, L. Waal, . Van-der, L. Jongman, P. Lugtenburg et al., Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study):28107. 14. Gea-Banacloche J. Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies, Eur J Cancer. nov Hematology Am Soc Hematol Educ Program, vol.452013, issue.16, p.41422, 2009.

L. Nesher and K. Rolston, Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy, Clinical Infectious Diseases, vol.50, issue.2, p.7117, 2013.
DOI : 10.1086/649554

D. Pauw, B. Walsh, T. Donnelly, J. Stevens, D. Edwards et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis. 15 juin, vol.46, issue.12, 2008.

C. Saillard, A. Sannini, L. Chow-chine, J. Blache, J. Brun et al., Febrile neutropenia in onco-hematology patients hospitalized in Intensive Care Unit] Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients):e92319. 21. Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies, pp.10-22593600, 2004.

J. Klastersky, M. Paesmans, E. Rubenstein, M. Boyer, L. Elting et al., The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients, Journal of Clinical Oncology, vol.18, issue.16, p.303851, 2000.
DOI : 10.1200/JCO.2000.18.16.3038

J. Micol, C. Chahine, P. Woerther, D. Ghez, F. Netzer et al., Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?, Clinical Microbiology and Infection, vol.20, issue.7, 2013.
DOI : 10.1111/1469-0691.12445

M. Mikulska, C. Viscoli, C. Orasch, D. Livermore, D. Averbuch et al., Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients, Journal of Infection, vol.68, issue.4, 2013.
DOI : 10.1016/j.jinf.2013.12.006

C. Viscoli, P. Bruzzi, and M. Glauser, An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients, European Journal of Cancer, vol.31, issue.12, pp.31-201322, 1995.
DOI : 10.1016/0959-8049(95)00292-8

. Cefepime, amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group, Clin Infect Dis. janv, vol.24, issue.1, p.4151, 1997.

M. Sanz, J. López, J. Lahuerta, M. Rovira, M. Batlle et al., Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association- 9802 prospective multicenter clinical trial, J Antimicrob Chemother. juill Leuk Lymphoma. juin, vol.5053, issue.16, p.106876, 2002.

E. Montassier, E. Batard, T. Gastinne, G. Potel, and M. De-la-cochetière, Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance, European Journal of Clinical Microbiology & Infectious Diseases, vol.95, issue.9
DOI : 10.3324/haematol.2009.020867

G. Bucaneve, A. Micozzi, M. Picardi, S. Ballanti, N. Cascavilla et al., Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia, Journal of Clinical Oncology, vol.32, issue.14, p.146371, 2014.
DOI : 10.1200/JCO.2013.51.6963

S. Ritchie, S. Palmer, R. Ellis-pegler, I. Gyssens, W. Kern et al., High-risk febrile neutropenia in Auckland: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients, Intern Med J. janv Haematologica. déc, vol.3798, issue.112, pp.2631-3418215, 2003.

C. Wu, C. Chen, H. Lee, C. Chang, P. Liu et al., Decreased antimicrobial resistance and defined daily doses after implementation of a clinical culture-guided antimicrobial stewardship program in a local hospital, Journal of Microbiology, Immunology and Infection, vol.50, issue.6, 2015.
DOI : 10.1016/j.jmii.2015.10.006